These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 22149368)

  • 41. Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study.
    Yang WL; Kouyos RD; Scherrer AU; Böni J; Shah C; Yerly S; Klimkait T; Aubert V; Hirzel C; Battegay M; Cavassini M; Bernasconi E; Vernazza P; Held L; Ledergerber B; Günthard HF; ;
    J Antimicrob Chemother; 2015 Dec; 70(12):3323-31. PubMed ID: 26362944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New nucleoside/nucleotide backbone options: a review of recent studies.
    Ruane PJ; DeJesus E
    J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S21-9. PubMed ID: 15319666
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal.
    Aragão F; Vera J; Vaz Pinto I
    PLoS One; 2012; 7(9):e44774. PubMed ID: 23028618
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Drug clinics. How I treat HIV infections. II. Nucleoside reverse transcriptase inhibitors].
    Moutschen M; Nkoghe D; Léonard P; Demonty J
    Rev Med Liege; 1997 Dec; 52(12):750-2. PubMed ID: 9481171
    [No Abstract]   [Full Text] [Related]  

  • 45. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lustgarten S; Squires KE; Meyer WA; Acosta EP; Schackman BR; Pilcher CD; Murphy RL; Maher WE; Witt MD; Reichman RC; Snyder S; Klingman KL; Kuritzkes DR;
    N Engl J Med; 2004 Apr; 350(18):1850-61. PubMed ID: 15115831
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current and future antiretroviral treatment options in paediatric HIV infection.
    Giaquinto C; Morelli E; Fregonese F; Rampon O; Penazzato M; de Rossi A; D'Elia R
    Clin Drug Investig; 2008; 28(6):375-97. PubMed ID: 18479179
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Investigational reverse transcriptase inhibitors for the treatment of HIV.
    Cory TJ; Midde NM; Rao P; Kumar S
    Expert Opin Investig Drugs; 2015; 24(9):1219-28. PubMed ID: 26088266
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nucleoside/nucleotide backbones for the treatment of HIV infection.
    Barreiro P; Jiménez-Nácher I; García B; García-Benayas T; Rivas P; Soriano V
    Curr Opin Investig Drugs; 2005 Aug; 6(8):812-22. PubMed ID: 16121688
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Clinical data I. Clinical experience with tenofovir in combination with nonnucleoside analogue transcriptase inhibitors].
    Bernardino de la Serna JI; Mora Rillo M; Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 Jun; 26 Suppl 8():7-12. PubMed ID: 19195432
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults.
    Bartlett JA; Fath MJ; Demasi R; Hermes A; Quinn J; Mondou E; Rousseau F
    AIDS; 2006 Oct; 20(16):2051-64. PubMed ID: 17053351
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
    Barry M; Mulcahy F; Merry C; Gibbons S; Back D
    Clin Pharmacokinet; 1999 Apr; 36(4):289-304. PubMed ID: 10320951
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
    Piliero PJ
    J Acquir Immune Defic Syndr; 2004 Sep; 37 Suppl 1():S2-S12. PubMed ID: 15319664
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rational approaches to resistance: nucleoside analogues.
    Mayers D
    AIDS; 1996 Nov; 10 Suppl 1():S9-13. PubMed ID: 8970670
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antiretroviral therapies.
    Owen WF
    Clin Podiatr Med Surg; 1998 Apr; 15(2):227-39. PubMed ID: 9576051
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
    Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Sierra Madero J; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S;
    Clin Infect Dis; 2016 Jul; 63(1):122-32. PubMed ID: 27048747
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intracellular phosphorylation of zidovudine (ZDV) and other nucleoside reverse transcriptase inhibitors (RTI) used for human immunodeficiency virus (HIV) infection.
    Peter K; Gambertoglio JG
    Pharm Res; 1998 Jun; 15(6):819-25. PubMed ID: 9647345
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Efavirenz Plus Two Nucleoside Reverse Transcriptase Inhibitors As Initial Antiretroviral Therapy for People with HIV: A Systematic Review.
    Rutherford GW; Horvath H
    PLoS One; 2016; 11(10):e0162775. PubMed ID: 27736859
    [TBL] [Abstract][Full Text] [Related]  

  • 59. InforMatrix nucleoside/nucleotide reverse transcriptase inhibitor 'backbones'.
    Schreij G; Janknegt R
    Expert Opin Pharmacother; 2007 Oct; 8 Suppl 1():S37-47. PubMed ID: 17931077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.
    Agwu A; Lindsey JC; Ferguson K; Zhang H; Spector S; Rudy BJ; Ray SC; Douglas SD; Flynn PM; Persaud D;
    AIDS Patient Care STDS; 2008 Jul; 22(7):545-52. PubMed ID: 18479228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.